23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Atea Pharmaceuticals, Inc. › 2025-2026

Atea Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Atea Pharmaceuticals, Inc.’s Form 8-K, filed June 22, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 133Asset managers, any item
  • 909Fund votes
  • June 18, 2026Meeting date

Results at a glance

Meeting of June 18, 2026: 5 items on Atea Pharmaceuticals, Inc.’s Form 8-K, filed June 22, 2026: 5 passed (calculated).

Dissent

Significant dissent: 1 director (43.6% against).

Notable dissent: 2 directors (14.4%, 12.9% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: BML Capital (13F, 8.4%, as of September 30, 2026)

Explore Atea Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Atea Pharmaceuticals, Inc.

These tallies are Atea Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 22, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Atea Pharmaceuticals, Inc. — official shareholder meeting results, meeting held June 18, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Jerome Adams, MD, MPH 28,798,012---- 22,275,6658,669,142 56%Passed (calculated)—
Elect Director: Howard Berman, PhD 44,466,627---- 6,607,0508,669,142 87%Passed (calculated)—
Elect Director: Barbara Duncan 43,697,098---- 7,376,5798,669,142 86%Passed (calculated)—
2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 58,894,207783,08165,531 --0 99%Passed (calculated)—
3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers 47,452,7592,977,290643,628 --8,669,142 94%Passed (calculated)—

Source: Atea Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 22, 2026 — read the filing on EDGAR.

How asset managers voted at the Atea Pharmaceuticals, Inc. 2025-2026 meeting

133 asset managers disclosed a vote on at least one Atea Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Barbara Duncan

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%WITHHELD
FOR: 43,697,098WITHHELD: 7,376,579
Details: description as filed, official tally, votes by 47 asset managers

Description as filed by funds: Election of Class III Directors: Barbara Duncan

Atea Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Barbara Duncan”): 43,697,098 for, 7,376,579 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 15,171,378 for, 980,628 withheld, 19,545 abstained.

FOR
FOR: 15,171,378ABSTAIN: 19,545WITHHOLD: 980,628
Largest asset managers voting on “Election of Class III Directors: Barbara Duncan” at Atea Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,910,0990 092For
Vanguard3,772,3400 219,965For
BlackRock2,883,9780 00For
Charles Schwab596,5190 00For
TIAA241,5050 00For
Equitable109,1850 075,590Mixed
American Century00 0171,034Withhold
JPMorgan157,7320 00For
Northern Trust00 0144,764Withhold
Lincoln Financial105,4190 04,025For
Goldman Sachs00 0107,065Withhold
QUANTITATIVE MASTER SERIES LLC105,7420 00For
AIG/SunAmerica00 076,420Withhold
ALPS ETF Trust00 073,473Withhold
Delaware/Macquarie00 070,000Withhold
MASTER INVESTMENT PORTFOLIO68,1100 00For
T. Rowe Price65,6410 00For
Brighthouse34,8410 019,000Mixed
EA Series Trust49,3640 00For
Dimensional00 048,664Withhold
Voya00 043,138Withhold
Global X00 030,344Withhold
Bridge Builder Trust30,3040 00For
Pacific Life27,2650 00For
SEI00 015,000Withhold

Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).

Elect Director: Howard Berman, PhD

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 44,466,627WITHHELD: 6,607,050
Details: description as filed, official tally, votes by 47 asset managers

Description as filed by funds: Election of Class III Directors: Howard Berman, PhD

Atea Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Howard Berman, PhD”): 44,466,627 for, 6,607,050 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 15,489,659 for, 662,348 withheld, 19,544 abstained.

FOR
FOR: 15,489,659ABSTAIN: 19,544WITHHOLD: 662,348
Largest asset managers voting on “Election of Class III Directors: Howard Berman, PhD” at Atea Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,910,0990 092For
Vanguard3,782,3060 200For
BlackRock2,883,9780 00For
Charles Schwab596,5190 00For
TIAA241,5050 00For
Equitable109,1850 075,590Mixed
American Century00 0171,034Withhold
JPMorgan157,7320 00For
Northern Trust144,7640 00For
Lincoln Financial105,4190 04,025For
Goldman Sachs107,0650 00For
QUANTITATIVE MASTER SERIES LLC105,7420 00For
AIG/SunAmerica00 076,420Withhold
ALPS ETF Trust00 073,473Withhold
Delaware/Macquarie00 070,000Withhold
MASTER INVESTMENT PORTFOLIO68,1100 00For
T. Rowe Price65,6410 00For
Brighthouse34,8410 019,000Mixed
EA Series Trust49,3640 00For
Dimensional00 048,664Withhold
Voya00 043,138Withhold
Global X30,3440 00For
Bridge Builder Trust30,3040 00For
Pacific Life27,2650 00For
SEI15,0000 00For

Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).

Elect Director: Jerome Adams, MD, MPH

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

56% Majority: yes · of votes cast

FOR 56%WITHHELD
FOR: 28,798,012WITHHELD: 22,275,665
Details: description as filed, official tally, votes by 47 asset managers

Description as filed by funds: Election of Class III Directors: Jerome Adams, MD, MPH

Atea Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jerome Adams, MD, MPH”): 28,798,012 for, 22,275,665 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 56% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 7,967,190 for, 7,325,218 withheld, 879,143 abstained.

FORWITHHOLD
FOR: 7,967,190ABSTAIN: 879,143WITHHOLD: 7,325,218
Largest asset managers voting on “Election of Class III Directors: Jerome Adams, MD, MPH” at Atea Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity1,475,2710 05,434,920Mixed
Vanguard3,772,2900 719,965For
BlackRock2,092,5400 791,4380Mixed
Charles Schwab00 0596,519Withhold
TIAA00 0241,505Withhold
Equitable109,1850 075,590Mixed
American Century00 0171,034Withhold
JPMorgan157,7320 00For
Northern Trust00 0144,764Withhold
Lincoln Financial105,4190 04,025For
Goldman Sachs00 0107,065Withhold
QUANTITATIVE MASTER SERIES LLC105,7420 00For
AIG/SunAmerica00 076,420Withhold
ALPS ETF Trust00 073,473Withhold
Delaware/Macquarie00 070,000Withhold
MASTER INVESTMENT PORTFOLIO00 68,1100Abstain
T. Rowe Price00 065,641Withhold
Brighthouse34,8410 019,000Mixed
EA Series Trust49,3640 00For
Dimensional00 048,664Withhold
Voya00 043,138Withhold
Global X00 030,344Withhold
Bridge Builder Trust30,3040 00For
Pacific Life27,2650 00For
SEI00 015,000Withhold

Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).

Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 5 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 47,452,759AGAINST: 2,977,290
Details: description as filed, official tally, votes by 133 asset managers

Description as filed by funds: Approval, on an advisory (non- binding) basis, of the compensation of the named executive officers of the Company.

Atea Pharmaceuticals, Inc.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers”): 47,452,759 for, 2,977,290 against, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 47 asset managers voting on “Approval, on an advisory (non- binding) basis, of the compensation of the named executive officers of the Comp” at Atea Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,910,1910 00For
Vanguard3,779,0293,294 30For
BlackRock2,883,9780 00For
Charles Schwab596,5190 00For
TIAA241,5050 00For
Equitable184,7750 00For
American Century0171,034 00Against
JPMorgan157,7320 00For
Northern Trust144,7640 00For
Lincoln Financial105,4194,025 00For
Goldman Sachs107,0650 00For
QUANTITATIVE MASTER SERIES LLC105,7420 00For
AIG/SunAmerica76,4200 00For
ALPS ETF Trust73,4730 00For
Delaware/Macquarie70,0000 00For
MASTER INVESTMENT PORTFOLIO68,1100 00For
T. Rowe Price65,6410 00For
Brighthouse53,8410 00For
EA Series Trust49,3640 00For
Dimensional048,664 00Against
Voya43,1380 00For
Global X030,344 00Against
Bridge Builder Trust30,3040 00For
Pacific Life27,2650 00For
SEI015,000 00Against

Fund voting reports, all 47 managers: 15,839,944 for, 324,407 against, 7,200 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 101 asset managers voting on “Approval, on an advisory (non- binding) basis, of the compensation of the named executive officers of the Comp” at Atea Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity11,949,8660 00For
BlackRock2,241,76112,745 00For
Bain Capital Life Sciences Investors, LLC2,210,3390 00For
GEODE CAPITAL MANAGEMENT, LLC1,731,4100 00For
State Street1,165,92419,700 00For
ACADIAN ASSET MANAGEMENT LLC819,1280 00For
Two Sigma781,9290 00For
Charles Schwab596,7960 00For
Renaissance530,4330 00For
Vanguard506,8110 00For
Northern Trust322,4622,156 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC260,5510 00For
DE Shaw251,6640 00For
Nuveen243,1030 00For
American Century0171,034 00Against
Wellington0143,567 00Against
T. Rowe Price143,0960 00For
Dimensional0136,454 00Against
AllianceBernstein121,3200 00For
MELLON INVESTMENTS Corp114,8800 00For
STATE OF WISCONSIN INVESTMENT BOARD98,7130 00For
STRS OHIO96,4000 00For
JPMorgan90,9310 00For
Aldebaran Capital, LLC088,935 00Against
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP77,9020 00For

Institutional-manager reports, all 101 managers: 24,835,050 for, 809,299 against. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 58,894,207AGAINST: 783,081
Details: description as filed, official tally, votes by 47 asset managers

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Atea Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026”): 58,894,207 for, 783,081 against, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 16,164,351 for, 3 against, 7,197 abstained.

FOR
FOR: 16,164,351AGAINST: 3ABSTAIN: 7,197
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCA” at Atea Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,910,1910 00For
Vanguard3,782,3233 00For
BlackRock2,883,9780 00For
Charles Schwab596,5190 00For
TIAA241,5050 00For
Equitable184,7750 00For
American Century171,0340 00For
JPMorgan157,7320 00For
Northern Trust144,7640 00For
Lincoln Financial109,4440 00For
Goldman Sachs107,0650 00For
QUANTITATIVE MASTER SERIES LLC105,7420 00For
AIG/SunAmerica76,4200 00For
ALPS ETF Trust73,4730 00For
Delaware/Macquarie70,0000 00For
MASTER INVESTMENT PORTFOLIO68,1100 00For
T. Rowe Price65,6410 00For
Brighthouse53,8410 00For
EA Series Trust49,3640 00For
Dimensional48,6640 00For
Voya43,1380 00For
Global X30,3440 00For
Bridge Builder Trust30,3040 00For
Pacific Life27,2650 00For
SEI15,0000 00For

Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).

Largest Atea Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 80,027,099 shares outstanding at the time of that meeting.

Fund voting reports: top Atea Pharmaceuticals, Inc. shareholders by shares voted on “Approval, on an advisory (non- binding) basis, of the compensation of the named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 8.63%
2Vanguard 4.73%
3BlackRock 3.60%
4Charles Schwab 0.75%
5TIAA 0.30%
6Equitable 0.23%
7American Century 0.21%
8JPMorgan 0.20%
9Northern Trust 0.18%
10Lincoln Financial 0.14%
Institutional-manager reports: top Atea Pharmaceuticals, Inc. shareholders by shares voted on “Approval, on an advisory (non- binding) basis, of the compensation of the named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 14.93%
2BlackRock 2.82%
3Bain Capital Life Sciences Investors, LLC 2.76%
4GEODE CAPITAL MANAGEMENT, LLC 2.16%
5State Street 1.48%
6ACADIAN ASSET MANAGEMENT LLC 1.02%
7Two Sigma 0.98%
8Charles Schwab 0.75%
9Renaissance 0.66%
10Vanguard 0.63%

Reported Atea Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Atea Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)11,950,772 14.93%Form 13F, quarter ended March 31, 2026
BlackRock8,435,437 10.54%Form 13F, quarter ended March 31, 2026
BML Investment Partners, L.P.7,490,000 9.36%Schedule 13G, filed February 9, 2026
Vanguard Group4,227,110 5.28%Form 13F, quarter ended March 31, 2026
Two Sigma1,864,164 2.33%Form 13F, quarter ended March 31, 2026
Geode Capital1,747,706 2.18%Form 13F, quarter ended March 31, 2026
State Street1,694,635 2.12%Form 13F, quarter ended March 31, 2026
Dimensional Fund Advisors1,255,484 1.57%Form 13F, quarter ended March 31, 2026
Renaissance Technologies1,166,400 1.46%Form 13F, quarter ended March 31, 2026
JPMorgan Chase940,157 1.17%Form 13F, quarter ended March 31, 2026

Percentages above are of 80,027,099 shares outstanding, as reported by Atea Pharmaceuticals, Inc. on its Form 10-Q dated May 11, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Atea Pharmaceuticals, Inc.'s shareholder meeting held June 18, 2026, in the 2025-2026 proxy season, 133 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 909 separate fund positions. On the most widely held item on that ballot — Approval, on an advisory (non- binding) basis, of the compensation of the named executive… — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Atea Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 22, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Atea Pharmaceuticals, Inc.’s 10-Q dated May 11, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Atea Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Atea Pharmaceuticals (AVIR) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/atea-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.